Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin
The study reveals that rifaximin, an antibiotic used to prevent liver disease, causes cross-resistance to daptomycin in vancomycin-resistant Enterococcus faecium (VREfm). This resistance is caused by amino acid changes in the bacterial RNA polymerase, leading to cell membrane remodeling and reduced antibiotic binding. This resistance is widespread globally, compromising the clinical use of daptomycin, a crucial last-resort intervention for multidrug-resistant pathogens.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!